FYI, this guy is not a Forbes writer. He is some Schmo who publishes his gripe/story on the Forbes web site. I didn't read his article, but you see on the page it says:
"The author is a Forbes contributor. The opinions expressed are those of the writer."
This is an ongoing deal with Forbes, and probably explains why the article is poorly written- it is basically this dude's blog posted on Forbes.com.
Here is an explanation of the "contributor" model at Forbes:
New rules for BC/BS blue card is also huge. How many labs actually have a contract with all blues plans? Not many I am sure. This is gonna help labcorp,quest and local labs. May actually keep more specimens from crossing state lines.